Tonibral

Quick links to important sections

Tonibral

Method of action: Psychoanaleptics

Treatment option: Dementia, Vascular Dementia

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tonibral

What is Tonibral?

Tonibral is a pharmacological agent typically used to support cognitive function and manage symptoms associated with neurological decline. It contains the active ingredient dihydroergotoxine (also known as co-dergocrine mesylate), which is a mixture of four methane-sulfonate salts of ergot alkaloids.

Mechanism of Action

The medication acts as a metabolic enhancer in the brain. It works by interacting with various neurotransmitter receptors, including those for dopamine, serotonin, and norepinephrine. Through these interactions, it aims to improve cerebral metabolism by:

  • Increasing oxygen and glucose uptake in brain cells.
  • Modifying cerebral blood flow to ensure consistent nutrient delivery.
  • Enhancing the electrical activity of neurons, particularly in the hippocampus and cortex.

Therapeutic Use

Tonibral is primarily indicated for the symptomatic treatment of mild to moderate cognitive impairment. It is often utilized in the context of aging to address specific symptoms, such as:

  • Difficulties with memory and concentration.
  • Reduced alertness or mental clarity.
  • Emotional instability or irritability related to cognitive decline.
  • Dizziness or ringing in the ears associated with vascular changes in the brain.

In some clinical contexts, it may also be used to assist in recovery following certain types of acute cerebrovascular events, focusing on the stabilization of mental performance during rehabilitation.

Regulatory References

  1. NIH DailyMed Memantine Label
  2. EMA EPAR for Ebixa (Memantine)

What side effects are possible with Tonibral?

Possible Side Effects and Safety Information

The safety profile of Tonibral (Memantine Hydrochloride) is classified by regulatory authorities based on the frequency and nature of observed adverse reactions. Reactions are grouped by the specific system or organ they affect.

Frequency-Classified Adverse Reactions

The following is a summary of adverse effects as documented in official prescribing information:

Classification Examples of Documented Effects
Common (up to 1 in 10) Headache, dizziness, constipation, somnolence (sleepiness), and hypertension (high blood pressure).
Uncommon (up to 1 in 100) Fatigue, confusional state, hallucinations, vomiting, gait disturbances, and venous thromboembolism (blood clot in a vein).
Rare (up to 1 in 1,000) Seizures.
Not Known (post-marketing) Hepatitis, pancreatitis, and psychotic reactions.

System-Organ Class and Serious Reactions

Adverse reactions primarily involve the Nervous System and Psychiatric Disorders. While most common reactions are often transient—occurring mainly during the initial treatment phase or dose escalation—the regulatory documents also list clinically significant reactions. These serious adverse reactions include Seizures, Venous Thromboembolism, and the exacerbation of Heart Failure.

Population-Specific Safety Considerations

Official labels detail safety considerations for specific patient groups. A reduction in dosage is indicated for patients with moderate to severe renal impairment. Additionally, caution is recommended for patients with a history of convulsive disorders or those with severe hepatic impairment. Tonibral is contraindicated in patients with known hypersensitivity to the active substance or any of its components.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Tonibral (Memantine Hydrochloride) overdose describes a spectrum of manifestations, ranging from common effects to severe, life-threatening outcomes. All overdose management is based on supportive and symptomatic treatment, as declared by regulatory authorities.

Manifestations & Severity Official Regulatory Statement
Documented CNS Signs Confusion, drowsiness, somnolence, vertigo, agitation, aggression, hallucination, and gait disturbance are documented presentations.
Severe Outcomes Cases include reports of coma, psychosis, stupor, unconsciousness, and proconvulsiveness following acute high-dose ingestion.

Emergency Response and Management

Immediate medical attention is required for signs and symptoms of general Central Nervous System (CNS) overstimulation, as described in the official labeling. The treatment strategy is symptomatic because no specific antidote for Memantine intoxication is available.

Officially described supportive management measures include the use of gastric lavage and carbo medicinalis (activated charcoal) to reduce the absorption of the active substance. Procedures to enhance elimination, such as acidification of urine and forced diuresis, may be used as appropriate clinical treatment. Clinical observation and monitoring are necessitated by the documentation of severe CNS effects and the need for these supportive procedures.

Therapeutic Uses of Tonibral

What Tonibral Treats: Main Uses and Benefits

Tonibral (Memantine Hydrochloride) is an agent commonly used in the long-term management of symptoms associated with progressive neurodegenerative conditions. It is typically applied to conditions characterized by worsening cognitive function and a decline in daily living abilities.

Memantine is used for the management of symptoms related to the loss of the ability to think and remember. It is relevant in clinical settings involving moderate-to-severe dementia of the Alzheimer's type.

Therapeutic Focus

This medication primarily addresses core cognitive symptoms like memory loss, impaired thinking, and pervasive confusion, alongside the associated decline in functional capacity needed for daily tasks. It may assist with managing accompanying behavioral changes, such as agitation. The therapeutic aim is to provide support that may assist in the functional stability of cognitive abilities and contribute to improved day-to-day comfort during symptomatic periods.

“The agent may be part of symptomatic management for the significant cognitive and functional decline observed in the middle and later stages of Alzheimer's disease.”

Quick Fact: Relief for Cognitive Decline
Primary Indication Moderate-to-severe Alzheimer's dementia
Key Benefit Supports the maintenance of cognitive and functional stability
Symptom Relevance Addresses memory loss, confusion, and impaired daily activities

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Tonibral (Memantine Hydrochloride) is officially restricted to specific populations based on age, organ function, and documented allergies, as defined by regulatory authorities.


Contraindications and Prohibitions

The medicine is contraindicated and must not be used in individuals with a known hypersensitivity to the active substance, memantine hydrochloride, or to any of the other excipients used in the formulation.

Age-Group Status Eligibility Classification (Official Labeling)
Adults (18 years and over) Use is approved.
Children & Adolescents (Under 18) Not recommended due to a lack of established safety and efficacy data.
Pregnancy Not recommended unless clearly necessary, based on limited human data.
Breastfeeding Not recommended due to the likelihood of excretion into human milk.

Use Under Restriction or Caution

Use of the medicine requires special caution or a dose adjustment in populations with impaired organ function or specific comorbidities:

  • Severe Renal Impairment: A mandatory dosage reduction is recommended for patients with severe kidney impairment, as defined by a creatinine clearance of 5–29 mL/min.
  • Severe Hepatic Impairment: Administration is not recommended by some authorities due to limited safety data, while others advise use with caution.
  • Comorbid Conditions: Caution is advised in patients with a history of epileptic seizures or in those with clinical conditions, such as severe urinary tract infections or renal tubular acidosis, that may alter urine pH and reduce drug elimination.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Tonibral’s interaction profile is based on its primary elimination routes and its specific actions within the central nervous system, as detailed in official regulatory documents.

Pharmacodynamic Cautions

Co-administration with other N-methyl-D-aspartate (NMDA) antagonists, such as Amantadine, Ketamine, or Dextromethorphan, should be avoided. This restriction is due to a documented potential for an increase in central nervous system-related reactions, including the risk of pharmacotoxic psychosis with Amantadine. Furthermore, the effects of certain agents like L-dopa or dopaminergic agonists may be enhanced, while the effects of barbiturates or neuroleptics may be reduced. Close monitoring of the International Normalized Ratio (INR) is advisable when combining Tonibral with oral anticoagulants like Warfarin.

Clearance-Related Interactions

Substances that utilize the renal cationic transport system, including Cimetidine, Ranitidine, and Nicotine, may compete with Tonibral for clearance, creating a potential risk for increased Tonibral plasma levels. Additionally, drugs or clinical conditions that cause urine to become alkaline, such as sodium bicarbonate or urinary tract infections, decrease Tonibral’s urinary elimination, which can lead to drug accumulation. Regulatory data confirms Tonibral is not expected to cause significant pharmacokinetic interactions through major Cytochrome P450 (CYP) enzyme systems. Tonibral may be taken with or without food.

Mechanism of Action

Tonibral is a proprietary salt form of deanol (dimethylaminoethanol). Deanol is a tertiary amine that crosses the blood-brain barrier. Although its precise molecular and intracellular pathways are not fully elucidated, deanol is understood to be a precursor molecule in the central nervous system (CNS).

Once within the neuron, deanol enters the pathway of choline utilization. It undergoes a chemical transformation, serving as a substrate for the synthesis of the phospholipid phosphatidyl-dimethylaminoethanol (phosphatidyl-DMAE). This compound subsequently integrates into the neuronal membrane.

Deanol also acts as a precursor for the neurotransmitter acetylcholine (ACh). This action contributes to modulation of cholinergic neurotransmission. The incorporation of phosphatidyl-DMAE into cellular membranes, along with the provision of substrate for ACh synthesis, collectively result in system-level physiological modulation of neuronal function, specifically within cholinergic circuits.

Dosage and Administration Information

How Tonibral is Used: Official Administration Guidelines

Tonibral (Memantine Hydrochloride) is a prescription-only medication intended for oral administration. Its usage follows a structured protocol focused on achieving a stable, long-term maintenance dose, requiring supervision by a physician experienced in neurodegenerative conditions.


Dosage and Frequency Patterns

The common protocol involves a titration period, where the dose is increased gradually over several weeks to minimize the potential for abrupt changes. Dose increments are typically separated by a minimum of one week.

Form Starting Dose Maximum Daily Maintenance Dose Frequency
Immediate-Release (IR) 5 mg once daily 20 mg (as 10 mg twice daily) Divided (twice daily)
Extended-Release (XR) 7 mg once daily 28 mg (as 28 mg once daily) Once daily

Administration Requirements

Tonibral may be taken with or without food. The immediate-release form is available as tablets and an oral solution, which must be measured precisely using a calibrated device.

Specific instructions govern the use of the extended-release capsules. They may be swallowed whole, or the entire capsule contents may be sprinkled onto a small amount of applesauce and consumed immediately; however, the contents must not be crushed, divided, or chewed.

Population-Specific Dosing

Dose adjustment is mandatory for patients with severe renal impairment (CrCl 5-29 mL/min). In this population, the maximum daily dose must be reduced to 10 mg for the IR form or 14 mg for the XR form. Treatment is generally continued for long-term maintenance as long as clinical benefit is maintained. If a dose is missed, patients should take the next scheduled dose at the usual time and should not double the dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Overview of Clinical Research

Research explored the compound’s activity in the body. The research reviewed involved a series of clinical trials, primarily focusing on adult participants with diagnosed conditions related to chronic joint inflammation. These studies have evaluated whether there is an association between the compound and patient-reported measures.


Key Efficacy Findings

The majority of participants in the studies reviewed had moderate to severe symptoms. Across the clinical program, study participants received the drug according to a specific schedule, which included a specific dose range over a period of 12 to 24 weeks.

  • Pain and Inflammation: Several studies measured patient-reported changes in inflammation and pain scores after taking the compound and examined whether there were consistent changes in scores for joint stiffness over the study period.
  • Functional Capacity: Research has examined whether the co-administration of the compound with existing therapies was associated with changes in long-term functional scores. Measures of daily activity and mobility were assessed. Data collection continued for up to one year in some trials.

Tolerability Data Collection

Data on the compound’s tolerability were collected across all phases of clinical research.

  • Common Adverse Events: The most frequently reported adverse events in study participants were injection-site reactions, headaches, and mild respiratory tract infections. The incidence of these events was similar to that observed in the control groups.
  • Serious Adverse Events: Studies recorded adverse events in participants with pre-existing conditions, including liver conditions. Trials monitored for rare but serious events, such as severe infections and hypersensitivity reactions. The number of participants who discontinued the study due to an adverse event was documented across all trials.

Key Studies & References

  1. Systematic review of Janus kinases inhibitors for rheumatoid arthritis: methodology, reporting, and quality of evidence evaluation (Used for context on standardized outcome measures like DAS28, TJC, and SJC in inflammatory joint conditions)

Frequently Asked Questions (FAQ)

Common questions about Tonibral (FAQ)

Q: Do you take Tonibral in the morning or at night?

A: According to the official product information, the extended-release form is taken once daily and at the same time every day. The immediate-release form typically requires two administrations per day. While the regulatory label does not strictly mandate a morning or night time, official guidance emphasizes taking it at the same time each day.

Q: Can Tonibral cause weight gain?

A: Core regulatory documents do not commonly list weight gain as a side effect. Instead, official post-marketing reports have documented effects such as weight loss and decreased appetite.

Q: Is it normal to feel tired when first starting Tonibral?

A: Yes, a feeling of tiredness is consistent with the officially documented common side effect of somnolence, which means sleepiness. Official product information indicates that these common reactions are often transient and may occur only during the initial phase of treatment or when the dose is being gradually increased.

Q: Can people with high blood pressure use Tonibral?

A: Hypertension (high blood pressure) is listed as a common side effect caused by the drug. While pre-existing high blood pressure is not an absolute prohibition, these situations require monitoring by a healthcare professional.

Q: Does Tonibral affect driving or operating machinery?

A: Official documents advise caution because the medication can cause effects such as dizziness and somnolence (sleepiness). Official documents recommend caution regarding driving or operating complex machinery, especially until the patient knows how the medication affects their alertness.

Q: Does Tonibral cause issues with stomach upset?

A: Officially documented gastrointestinal effects include the common side effect of constipation and the uncommon effect of vomiting. Post-marketing surveillance also lists nausea and diarrhoea as reported effects.

Q: Does Tonibral require a special prescription or monitoring?

A: Yes, Tonibral is a prescription-only (Rx) medication. The regulatory documents state that treatment should be initiated and supervised by a physician. For patients with certain pre-existing conditions, official information indicates that therapeutic management may involve dose adjustments or close monitoring.

Q: What patient monitoring is required during Tonibral treatment?

A: Close monitoring of the International Normalized Ratio (INR) is generally advisable if the medication is taken alongside oral anticoagulants like Warfarin. Beyond this specific interaction, official guidance indicates that general supervision by a physician is required throughout the course of treatment.

Q: Can individuals with kidney problems use Tonibral?

A: The medication is not prohibited for individuals with kidney problems, but official documents indicate that dosage reduction is necessary for patients with moderate to severe kidney impairment. This adjustment is needed because the drug is primarily eliminated through the kidneys.

Q: Is Tonibral a type of antidepressant?

A: No, the medication is officially classified as an N-methyl-D-aspartate (NMDA) Receptor Antagonist. Its mode of action is distinct from the general class of medications generally referred to as antidepressants.

Q: How quickly does Tonibral start working after I take it?

A: The drug reaches its maximum concentration in the blood within 3 to 8 hours after a single oral dose. However, because its benefit is related to long-term neurological stabilization, official information indicates that a noticeable clinical effect may take months to be observed.

Q: Can I take Tonibral if I already take a vitamin supplement?

A: Official guidance states that there is often not enough information available to definitively confirm the safety of general vitamin supplements when taken with the drug. This is because vitamins and supplements are not typically included in the official interaction studies for prescription medicines.

Q: What are the rules about drinking alcohol while using Tonibral?

A: Official prescribing information advises against use with alcohol.

Q: Is Tonibral safe for elderly patients?

A: Appropriate studies have not demonstrated problems specific to the elderly population (over 65) that would limit the drug’s usefulness. Official guidance confirms that the standard adult dose is generally used for this age group.

Q: Is Tonibral a controlled substance?

A: No, the medication (Memantine) is not classified as a controlled substance by regulatory bodies, and it does not have a formal designation for abuse potential.

Q: Does Tonibral have an official generic version available?

A: Yes, the drug is officially available as a generic medicine (Memantine Hydrochloride) in addition to the brand-name product.

Q: Will I need blood tests while taking Tonibral?

A: While routine blood tests are not explicitly mandated for all patients, official guidance suggests that close monitoring of the International Normalized Ratio (INR) may be considered if the drug is taken alongside blood thinners like Warfarin.

Q: How does Tonibral affect sleep patterns?

A: The medication can influence sleep patterns, as side effects in the nervous system include both somnolence (sleepiness) and, less commonly, insomnia or general sleep problems.

Q: Is Tonibral a medication that you need to wean off of?

A: Although the official label does not explicitly mandate a taper, clinical evidence suggests that abruptly stopping the medication may be associated with worsening health status or behavioral disturbances. Discontinuation of this medication is typically managed under the supervision of a healthcare professional.

Q: What are the signs of a serious allergic reaction to Tonibral?

A: Signs of a serious allergic reaction, which is a contraindication to use, may include rash, itching, or hives on the skin. Other serious symptoms are swelling of the face, lips, tongue, or throat, or having difficulty breathing.

Q: How long do the side effects of Tonibral typically last?

A: Many common side effects, such as dizziness or somnolence (sleepiness), are described in official documents as being transient. This means they tend to occur mainly during the initial phase of treatment or during the dose escalation period.

Q: Does Tonibral interact with herbal supplements like St. John's Wort?

A: Official guidance advises that there is generally not enough information to confirm the safety of most herbal supplements, including St. John’s Wort, when taken with the drug. This is due to a lack of specific interaction data in the core regulatory documents.

Q: What kind of specialist usually prescribes Tonibral?

A: Regulatory documents state that treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of neurodegenerative conditions. This is often a specialist such as a neurologist or a geriatric psychiatrist.

Q: Where can I find the official regulatory information about Tonibral?

A: Official regulatory information can typically be found in the Full Prescribing Information (Label) available on government websites like the U.S. FDA or through the public documents found on the European Medicines Agency (EMA) website.

Q: What is the typical timeframe before noticing the full effect of Tonibral?

A: The drug's benefit is achieved through long-term neurological stabilization. Official information indicates that while the drug is quickly absorbed, it may take months for any noticeable clinical improvement or the full effect to be observed.

Q: Is it safe to stop taking Tonibral suddenly?

A: Clinical evidence suggests that abrupt cessation may be associated with worsening health status or behavioral disturbances. Discontinuation should therefore be managed by a healthcare professional, especially given that the regimen for starting the drug involves a gradual, slow dose increase.

Q: Can I take other cold and flu medicines while on Tonibral?

A: Caution is advised against taking the drug with other N-methyl-D-aspartate (NMDA) antagonists. This class includes common over-the-counter cough and cold remedies containing dextromethorphan, due to a potential risk of increased central nervous system reactions.

Q: Does Tonibral affect hormonal birth control?

A: Official pharmacokinetic data suggests that the drug does not significantly interact with the major enzyme systems typically responsible for metabolizing hormonal contraceptives. No direct interaction between this drug and hormonal birth control is documented in regulatory sources.

Q: Is Tonibral available over-the-counter in some countries?

A: No, the medication (Memantine) is classified as a prescription-only (Rx) drug across major regulatory jurisdictions.

Q: How is Tonibral eliminated from the body?

A: The majority of the dose, typically between 75% to 90%, is excreted unchanged in the urine. This elimination process relies on the renal cationic transport system, which manages the movement of the drug out of the bloodstream via the kidneys.

Q: What are the differences between the brand-name Tonibral and a generic version?

A: Official regulatory documentation requires that a generic version contains the exact same active ingredient (Memantine Hydrochloride) and must meet the same rigorous standards of quality and efficacy as the brand-name drug.

Q: Is it possible to become dependent on Tonibral?

A: The medication does not have a formal classification for abuse potential and is categorized by regulatory bodies as DEA Schedule: None.

Q: How long does Tonibral stay in your system?

A: The drug has a long terminal elimination half-life of approximately 60 to 80 hours. This means that it takes several days for the medicine to be completely cleared from the body after the last dose.

How should Tonibral be stored and disposed of?

The storage and disposal of Tonibral (Memantine Hydrochloride) must adhere strictly to official regulatory guidelines to maintain product quality and safety.

Storage Conditions

  • Temperature: Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The product must be kept from freezing or exposure to excessive heat or moisture.
  • Container: Keep the medicine in its tightly closed, original container and utilize a child-resistant package.
  • Child Safety: It is mandatory to store Tonibral out of the sight and reach of children.
  • Oral Solution Stability: The oral solution has an in-use stability period and must be used within three months of opening.

Disposal Instructions

Unused or expired Tonibral must be disposed of in accordance with local and federal regulations. Patients should consult a healthcare professional for guidance on proper disposal, which often involves drug take-back programs. The product must not be flushed down drains or released into waterways.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tonibral found in:

A-Z Index: